ChatGPT dog cancer vaccine story becomes startup with Y Combinator backing

Paul Conyngham, an Australian tech entrepreneur, announced the launch of Gamgee, a startup centered on personalized mRNA cancer vaccines for dogs. The company's origin story centers on Rosie, Conyngham's Staffordshire bull terrier-Shar Pei mix. Conyngham used ChatGPT and computational genomics to design a personalized mRNA cancer vaccine for Rosie's tumors, and according to his account, several of her tumors shrank following the treatment. Conyngham, who emphasizes that he is not a biologist, credits the intervention with adding years to Rosie's life. The startup's website features Rosie prominently, including in an AI-generated anime launch video, and displays a slideshow of dogs with purported cancer diagnoses to underscore the company's mission.

Gamegee has secured backing from Y Combinator, the renowned tech incubator, and is currently recruiting for its first clinical trials in Australia with a global waitlist. On its website, aimed at veterinarians, Gamgee highlights its "first documented case," which showed a roughly 75 per cent tumor reduction, and promises that the treatment requires less than 20 minutes of veterinary time, no new clinical workflows, and delivery of a finished vaccine in around four weeks—though the company cautions that this timeline is based on a single case and may vary. Costs are not disclosed. Gamgee also states it is collaborating with the University of Queensland and institutes at the University of New South Wales, and Conyngham is actively seeking funders and study partners.

However, the scientific legitimacy of Conyngham's narrative has been questioned. Researchers who examined the story told The Verge that the science is considerably messier than Conyngham's account presents. The exact role AI played in the vaccine design was unclear, and researchers said the broad claims gave the technology too much credit while minimizing the role of human expertise. Most critically, Rosie did not receive the mRNA vaccine as a standalone treatment; it was administered alongside another therapy, making it scientifically impossible to determine whether the vaccine was responsible for her improvement or whether the other treatment, or a combination, caused the tumor shrinkage.

Despite these scientific caveats, the story has attracted institutional support and investment. Gamgee's ambitions extend well beyond dogs and other animals to personalized treatments for humans and a range of diseases. The company's website promises that AI and genetics will be harnessed to develop these broader treatments. As The Verge notes, for a startup built around a single dog whose improvement cannot be clearly attributed to the vaccine at its core, this represents a grand ambition.